EKTA.B

50.3

-3.08%↓

EKTA.B

50.3

-3.08%↓

EKTA.B

50.3

-3.08%↓

EKTA.B

50.3

-3.08%↓

EKTA.B

50.3

-3.08%↓

Search

Alligator Bioscience AB

Closed

0.005 -16.67

Overview

Share price change

24h

Current

Min

0.005

Max

0.006

Key metrics

By Trading Economics

Income

1.9M

-60M

Sales

40M

42M

EPS

-0.006

Profit margin

-143.826

Employees

46

EBITDA

56M

-3.8M

Market Stats

By TradingEconomics

Market Cap

120M

Previous open

16.68

Previous close

0.005

Alligator Bioscience AB Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 kwi 2025, 23:04 UTC

Top News

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 kwi 2025, 22:40 UTC

Major Market Movers

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 kwi 2025, 22:18 UTC

Acquisitions, Mergers, Takeovers

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 kwi 2025, 18:51 UTC

Acquisitions, Mergers, Takeovers

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 kwi 2025, 23:43 UTC

Market Talk

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 kwi 2025, 23:41 UTC

Market Talk

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 kwi 2025, 22:22 UTC

Acquisitions, Mergers, Takeovers

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 kwi 2025, 22:21 UTC

Acquisitions, Mergers, Takeovers

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 kwi 2025, 21:43 UTC

Top News
Earnings

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 kwi 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 kwi 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 kwi 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 kwi 2025, 20:43 UTC

Market Talk

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 kwi 2025, 20:34 UTC

Top News

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 kwi 2025, 20:23 UTC

Top News

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 kwi 2025, 20:15 UTC

Acquisitions, Mergers, Takeovers

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 kwi 2025, 19:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 kwi 2025, 19:55 UTC

Market Talk

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 kwi 2025, 19:21 UTC

Market Talk

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 kwi 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 kwi 2025, 18:45 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 kwi 2025, 18:45 UTC

Market Talk

Gold Drops In Tariff Fallout -- Market Talk

3 kwi 2025, 18:39 UTC

Market Talk

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 kwi 2025, 18:38 UTC

Top News

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 kwi 2025, 18:30 UTC

Top News

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 kwi 2025, 18:20 UTC

Market Talk

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 kwi 2025, 18:18 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 kwi 2025, 18:17 UTC

Market Talk

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 kwi 2025, 18:04 UTC

Market Talk

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 kwi 2025, 17:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Alligator Bioscience AB Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Alligator Bioscience AB

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company's product portfolio includes Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ALG.APV-527, a bispecific antibody that targets the 4-1BB and 5T4 molecules, which is in phase 1 clinical trial for the treatment of solid metastatic tumors; and ATOR-1017, an immunostimulatory antibody, which is in phase 1 clinical trial for the treatment of metastatic cancer. In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; ALLIGATOR-FAB, which is built on multiple scaffolds with optimal drug development properties to further increase the structural diversity of generated antibodies; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; MacroGenics, Inc.; Biotheus Inc.; BioArctic AB; and Abclon Inc. The company was founded in 2000 and is headquartered in Lund, Sweden.